Pharmacogenomic strategies in personalizing anticancer therapy

Abstract

Pharmacogenomics holds transformative potential for personalizing anticancer therapy, tailoring treatments based on genetic profiles to optimize efficacy and minimize adverse effects. This review explores the integration of pharmacogenomic strategies into cancer treatment, highlighting the impact of genetic markers on drug metabolism and therapy outcomes. Key pharmacogenomic markers such as Cytochrome P450 enzymes, TPMT, UGT1A1, KRAS, BRAF, and HER2 are examined to demonstrate their influence on the pharmacokinetics and pharmacodynamics of anticancer drugs. The review also addresses the challenges and opportunities in implementing pharmacogenomic testing in clinical settings, including issues related to genetic diversity, ethical considerations, and the economic implications of personalized medicine. Ultimately, this paper aims to underscore the importance of pharmacogenomic data in refining anticancer therapies, fostering a move towards more individualized treatment plans that promise improved patient outcomes.